Mar 24, 2026 ·The risks of side effects of particular concern fortype1diabetespatientstakingGLP-1-RAs—severe hypoglycemia and diabetic ketoacidosis; a severe lack of insulin, causing acid accumulation in the blood—were not increased among thepatientstaking these drugs. The findings were published online March 19 in Nature Medicine.
Aug 27, 2025 ·Glucagon-like peptide-1receptor agonists (GLP-1RAs) have demonstrated significant cardiovascular (CV) benefits, particularlyin patientswithdiabetesmellitus, but the safety and efficacy of differentGLP-1RAs across diverse populations remain insufficiently defined.
Oct 21, 2022 ·Glucagon-like peptide-1receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are used off-label in the management oftype1diabetesmellitus (T1DM) in real-world practice as adjuvant therapies to insulin. There are few real-world data regarding efficacy and safety of this practice.
A narrative review found thatGLP-1RAs when combined with lifestyle interventions, led to an average weight loss difference of 4% to 6.2%in patientswithdiabetes, whereas in those withoutdiabetes, the weight loss ranged from 6.1% to 17.4%.
Mar1, 2025 ·MethodsPatientswith Type1diabeteswith concomitantGLP-1agonists used for at least one year were included. Observed outcomes were the change in A1C, weight, and basal insulin use compared at baseline and 12 months using mixed models repeated measures.
